MAVDA: a central hub to discover oral antiviral drugs for COVID-19 and other viruses
Official title: MAVDA: High Throughout Screening and Bioassay Core for Metropolitan AntiViral
Funded at Hackensack University Medical Center · NIH-11617028 · Data updated 2026-11-12
A central core facility helps scientists rapidly screen and study potential oral antiviral drugs to fight SARS-CoV-2 and other emerging viruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | May 16, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $269,750 |
| NIH project number | 4U19AI171401-02 |
| Project ID | NIH-11617028 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals affected by or at risk from COVID-19 or related viral infections where future antivirals may be applicable.
✕Less likely to help
This grant funds a research core and does not involve direct patient participation or immediate treatment.
What this research studies
This NIH grant funds a high-throughput screening core at Hackensack University Medical Center to identify potent, drug-like compounds that can reach effective levels in the body. The core will generate data on how strongly compounds bind to targets, how they behave in concentration-response tests, and how they interact enthalpy- and entropy-wise, guiding next steps in medicinal chemistry. Researchers will also test promising compounds in high-throughput viral assays to see if they reduce virus activity in cells. By collaborating with project leaders and medicinal chemists, the core aims to accelerate discovery of orally bioavailable antivirals for current and future pandemics.
Why it matters
Potential benefit: If successful, patients could benefit from faster development of effective oral antivirals for COVID-19 and other pandemic-threat viruses.
How similar studies have gone: Previous antiviral screening efforts have yielded promising lead compounds; this project focuses on a rapid, centralized screening workflow to advance candidates.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Glickman, Joseph Fraser — Hackensack University Medical Center
- Study coordinator: Glickman, Joseph Fraser
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.